Literature DB >> 11156387

Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition.

X Yang1, A T Ferguson, S J Nass, D L Phillips, K A Butash, S M Wang, J G Herman, N E Davidson.   

Abstract

Recent findings have established a connection between DNA methylation and transcriptionally inactive chromatin characterized by deacetylated histones. Because the absence of estrogen receptor alpha (ERalpha) gene expression has been associated with aberrant methylation of its CpG island in a significant fraction of breast cancers, we tested whether histone deacetylase activity contributes to the transcriptional inactivation of the methylated ER gene in a panel of ER-negative human breast cancer cells. Treatment of these cells with trichostatin A, a specific histone deacetylase inhibitor, led to dose- and time-dependent re-expression of ER mRNA as detected by reverse transcription-PCR without alteration in ERalpha CpG island methylation. Trichostatin A-induced ER re-expression was associated with increased sensitivity to DNase I at the ER locus in MDA-MB-231 cells. These data implicate inactive chromatin mediated by histone deacetylation as a critical component of ER gene silencing in human breast cancer cells. Therefore, histone deacetylation may be a potential target for therapeutic intervention in the treatment of a subset of ER-negative breast cancers.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11156387

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  89 in total

1.  Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer.

Authors:  Yutaka Kondo; LanLan Shen; Jean-Pierre J Issa
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

Review 2.  Molecular and cellular determinants of estrogen receptor alpha expression.

Authors:  Joseph J Pinzone; Holly Stevenson; Jeannine S Strobl; Patricia E Berg
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

3.  ERalpha and ERbeta expression and transcriptional activity are differentially regulated by HDAC inhibitors.

Authors:  V Duong; A Licznar; R Margueron; N Boulle; M Busson; M Lacroix; B S Katzenellenbogen; V Cavaillès; G Lazennec
Journal:  Oncogene       Date:  2006-03-16       Impact factor: 9.867

4.  Epigenetic Reactivation of Estrogen Receptor: Promising Tools for Restoring Response to Endocrine Therapy.

Authors:  Neeraj K Saxena; Dipali Sharma
Journal:  Mol Cell Pharmacol       Date:  2010

5.  Regulation of demethylation and re-expression of RASSF1A gene in gastric cancer cell lines by combined treatment of 5-Aza-CdR and NaB.

Authors:  Wen-Jing Shen; Dong-Qiu Dai; Yue Teng; Hong-Bo Liu
Journal:  World J Gastroenterol       Date:  2008-01-28       Impact factor: 5.742

6.  A chimeric SERM-histone deacetylase inhibitor approach to breast cancer therapy.

Authors:  Hitisha K Patel; Marton I Siklos; Hazem Abdelkarim; Emma L Mendonca; Aditya Vaidya; Pavel A Petukhov; Gregory R J Thatcher
Journal:  ChemMedChem       Date:  2013-08-16       Impact factor: 3.466

7.  DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine.

Authors:  Jia Yu; Bo Qin; Ann M Moyer; Somaira Nowsheen; Tongzheng Liu; Sisi Qin; Yongxian Zhuang; Duan Liu; Shijia W Lu; Krishna R Kalari; Daniel W Visscher; John A Copland; Sarah A McLaughlin; Alvaro Moreno-Aspitia; Donald W Northfelt; Richard J Gray; Zhenkun Lou; Vera J Suman; Richard Weinshilboum; Judy C Boughey; Matthew P Goetz; Liewei Wang
Journal:  J Clin Invest       Date:  2018-04-30       Impact factor: 14.808

8.  Specific activity of class II histone deacetylases in human breast cancer cells.

Authors:  Vanessa Duong; Caroline Bret; Lucia Altucci; Antonello Mai; Céline Duraffourd; Julie Loubersac; Pierre-Olivier Harmand; Sandrine Bonnet; Sergio Valente; Thierry Maudelonde; Vincent Cavailles; Nathalie Boulle
Journal:  Mol Cancer Res       Date:  2008-12       Impact factor: 5.852

9.  Epigenetic Therapy in Breast Cancer.

Authors:  Maryam B Lustberg; Bhuvaneswari Ramaswamy
Journal:  Curr Breast Cancer Rep       Date:  2011-03

10.  Mutant p53 binds to estrogen receptor negative promoter via DNMT1 and HDAC1 in MDA-MB-468 breast cancer cells.

Authors:  Rita Arabsolghar; Tayebeh Azimi; Mozhgan Rasti
Journal:  Mol Biol Rep       Date:  2012-12-15       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.